Glomerulonefritis rápidamente progresiva mediada por inmunocomplejos (tipo II). Revisión de la literatura

  • John Fredy Nieto-Ríos Hospital Pablo Tobón Uribe, Universidad de Antioquia
  • Miguel Bernardo Giraldo-Serna Universidad de Antioquia
  • Camilo Andrés García- Prada Hospital Universitario San Vicente Fundación, IPS Sura
  • Andrés Felipe Lotero-Cadavid Universidad Pontificia Bolivariana
  • Lina María Serna-Higuita Universidad de Tübingen
  • Luis F. Arias Universidad de Antioquia
Palabras clave: glomerulonefritis, complejos inmunes, nefropatía por inmunoglobulina A, púrpura de Schönlein-Henoch, insuficiencia renal terminal, biopsia, esteroides.

Resumen

La glomerulonefritis rápidamente progresiva mediada por complejos inmunes (GMNRP II) es un síndrome clínico caracterizado por el rápido deterioro de la función renal asociado a hematuria, edemas y oliguria. Histológicamente se manifiesta como una glomerulonefritis crescéntica, con la presencia de depósitos granulares en la inmunofluorescencia. Aunque es una enfermedad rara, es grave y puede evolucionar a una enfermedad renal crónica, por lo cual es fundamental su identificación temprana. A continuación, se presenta una revisión sobre este tipo de glomerulonefritis, con énfasis en su etiología y en las opciones terapéuticas existentes en la actualidad.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

John Fredy Nieto-Ríos, Hospital Pablo Tobón Uribe, Universidad de Antioquia

Médico, Especialista en Medicina Interna, Especialista en Nefrología, Hospital Pablo Tobón Uribe, Universidad de Antioquia. Medellín, Colombia.

Miguel Bernardo Giraldo-Serna, Universidad de Antioquia

Médico, Residente de Medicina Interna, Universidad de Antioquia. Medellín Colombia.

Camilo Andrés García- Prada, Hospital Universitario San Vicente Fundación, IPS Sura

Médico, Especialista en Medicina Interna, Especialista en Nefrología, Hospital Universitario San Vicente Fundación, IPS Sura. Medellín, Colombia.

Andrés Felipe Lotero-Cadavid, Universidad Pontificia Bolivariana

Médico, Residente de Medicina Interna, Universidad Pontificia Bolivariana. Medellín, Colombia.

Lina María Serna-Higuita, Universidad de Tübingen

Médica, Especialista en Pediatría, Especialista en Nefrología Pediátrica, MSc en Epidemiología. Docente e Investigadora Asociada, Universidad de Tübingen. Tübingen, Alemania.

Luis F. Arias, Universidad de Antioquia

Médico, Especialista en Patología, PhD en Medicina. Docente, Universidad de Antioquia. Medellín, Colombia.

Referencias bibliográficas

Ramos JM, Medina AB, Fernández MP. Glomerulonefritis agudas y rápidamente progresivas. Medicine 2019;12:4717-4724. https://doi.org/10.1016/j.med.2019.05.029.

Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 1988;11:449-464. https://doi.org/10.1016/s0272-6386(88)80079-9.

Parmar MS, Bashir K. Crescentric Glomerulonephritis. StatPearls. Treasure Island (FL): Stat-Pearls Publishing; 2021. Acceso 15 de abril de 2020. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK430727/.

Sethi S, Haas M, Markowitz GS, D'Agati VD, Rennke HG, Jennette JC, et al. Mayo Clinic/Renal Pathology Society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol 2016;27:1278-1287. https://doi.org/10.1681/asn.2015060612.

Appel G, Radhakrishnan J. Enfermedades glomerulares y síndromes nefróticos. In: Goldman L, Schaefer A, eds. Tratado de Medicina Interna. Ámsterdam, Países Bajos: Elsevier; 2016. p. 783-793.

Johnson R, Feehally J, Floege J, Tonelli M. Introduction to glomerular disease : Clinical pre sentations. Comprehensive Clinical Nephrology. Ámsterdam, Países Bajos: Elsevier; 2019. p. 184-198.

Praga-Terente M. Nefropatías glomerulares primarias. In: Rozman-Borstnar C, Cardellach-López F, eds. Medicina Interna. España: ACME Libreria Ciencia Medicina; 2020. p. 845-854.

Baldwin DS, Neugarten J, Feiner HD, GluckM, Spinowitz B. The existence of a protracted course in crescentic glomerulonephritis. Kidney Int 1987;31:790-794. https://doi.org/10.1038/ki.1987.67.

Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmun Rev 2014;13:723-729. https://doi.org/10.1016/j.autrev.2014.02.007.

Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int 2003;63:1164-1177. https://doi.org/10.1046/j.1523-1755.2003.00843.x.

Choudhury TA, Singh RG, Singh S, Singh TB, Rathore SS. Clinicopathologic spectrum of crescentic glomerulonephritis: a hospital-based study. Saudi J Kidney Dis Transpl 2014;25:689-696. https://doi.org/10.4103/1319-2442.132241.

Kidney Disease: Improving Global Outcomes (KDIGO). Chapter 10: Immunoglobulin A nephropathy. Kidney Int Suppl (2011) 2012;2:209-217. https://doi.org/10.1038/kisup.2012.23.

Aguiar A, Alvarer P, Paz-Wasiuchnik V, Abib A, Ciliberti E, Moretti L, et al. Glomerulonefritis rápidamente progresiva en ancianos. Medicina (Buenos Aires) 2013;73:148-152.

Wu T, Peng J, Meng T, Liu Q, Ao X, Lin W, et al. Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis. Exp Ther Med 2019;18:3984-3990. https://doi.org/10.3892/etm.2019.8023.

Chen M, Cui Z, Zhao MH. ANCA-associated vasculitis and anti-GBM disease: the experience in China. Nephrol Dial Transplant 2010;25:2062-2065. https://doi.org/10.1093/ndt/gfq134.

Bonsib SM. Glomerular basement membrane discontinuities. Scanning electron microscopic study of acellular glomeruli. Am J Pathol 1985;119:357-360.

Atkins RC, Nikolic-Paterson DJ, Song Q, Lan HY. Modulators of crescentic glomerulonephritis. J Am Soc Nephrol 1996;7:2271-2278. https://doi.org/10.1681/asn.V7112271.

Praga M, Gutierrez-Millet V, Navas JJ, Ruilope LM, Morales JM, Alcazar JM, et al. Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy. Kidney Int 1985;28:69-74. https://doi.org/10.1038/ki.1985.120.

Bennett WM, Kincaid-Smith P. Macroscopic hematuria in mesangial IgA nephropathy: correlation with glomerular crescents and renal dysfunction. Kidney Int 1983;23:393-400. https://doi.org/10.1038/ki.1983.32.

Arimura Y, Muso E, Fujimoto S, Hasegawa M, Kaname S, Usui J, et al. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol 2016;20:322-341. https://doi.org/10.1007/s10157-015-1218-8.

Bruns FJ, Adler S, Fraley DS, Segel DP. Longterm follow-up of aggressively treated idiopathic rapidly progressive glomerulonephritis. Am J Med 1989;86:400-406. https://doi.org/10.1016/0002-9343(89)90336-7.

Bagga A, Menon S. Rapidly progressive glomerulonephritis. In: Geary D, Schaefer F, eds. Comprehensive Pediatric Nephrology Mosby. 1st ed; 2008. p. 319-328.

Rodríguez-Iturbe B. Epidemic poststreptococcal glomerulonephritis. Kidney Int 1984;25:129- 136. https://doi.org/10.1038/ki.1984.19.

Nissenson AR, Baraff LJ, Fine RN, Knutson DW. Poststreptococcal acute glomerulonephritis: fact and controversy. Ann Intern Med 1979;91:76-86. https://doi.org/10.7326/0003-4819-91-1-76.

Blyth CC, Robertson PW, Rosenberg AR. Post-streptococcal glomerulonephritis in Sydney: a 16-year retrospective review. J Paediatr Child Health 2007;43:446-450. https://doi.org/10.1111/j.1440-1754.2007.01109.x.

Sanjad S, Tolaymat A, Whitworth J, Levin S. Acute glomerulonephritis in children: a review of 153 cases. South Med J 1977;70:1202-1206. https://doi.org/10.1097/00007611-197710000-00015.

Sagel I, Treser G, Ty A, Yoshizawa N, Kleinberger H, Yuceoglu AM, et al. Occurrence and nature of glomerular lesions after group Glomerulonefritis rápidamente progresiva mediada por inmunocomplejos (tipo II). A streptococci infections in children. Ann Intern Med 1973;79:492-499. https://doi.org/10.7326/0003-4819-79-4-492.

Gutiérrez E, González E, Hernández E, Morales E, Martínez MA, Usera G, et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol 2007;2:51-57. https://doi.org/10.2215/cjn.02670706.

Peru H, Soylemezoglu O, Bakkaloglu SA, Elmas S, Bozkaya D, Elmaci AM, et al. Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period. Clin Rheumatol 2008;27:1087-1092. https://doi.org/10.1007/s10067-008-0868-2.

Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 2005;35:143-153. https://doi.org/10.1016/j.semarthrit.2005.08.007.

Peeters V, De Raeve L. Blistering eruptions in Henoch-Schönlein syndrome: more common than assumed. Eur J Pediatr 2018;177:475-476. https://doi.org/10.1007/s00431-017-2990-0.

Wu CS, Tung SY. Henoch-Schönlein purpura complicated by upper gastrointestinal bleeding with an unusual endoscopic picture. J Clin Gastroenterol 1994;19:128-131. https://doi.org/10.1097/00004836-199409000-00011.

Nathan K, Gunasekaran TS, Berman JH. Recurrent gastrointestinal Henoch-Schönlein purpura. J Clin Gastroenterol 1999;29:86-89. https://doi.org/10.1097/00004836-199907000-00022.

Johnson EF, Lehman JS, Wetter DA, Lohse CM, Tollefson MM. Henoch-Schönlein purpura and systemic disease in children: retrospective study of clinical findings, histopathology and direct immunofluorescence in 34 paediatric patients. Br J Dermatol 2015;172:1358-1363. https://doi.org/10.1111/bjd.13472.

Greenhall GH, Salama AD. What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J 2015;8:143-150. https://doi.org/10.1093/ckj/sfv008.

Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-1226. https://doi.org/10.1002/art.34359.

Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-1286. https://doi.org/10.1136/annrheumdis-2012-202844.

Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, Brito-Zeron P, Cuadrado MJ, Sanna G, et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol 2011;40:159-169. https://doi.org/10.1007/s12016-010-8205-3.

Tsanian M, Solov'ev SK, Torgashina AV, Aleksandrova EN, Radenska-Lopovok SG, Nikolaeva EV, et al. [Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment]. Ter Arkh 2014;86:40-49.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 2017;28:1306-1313. https://doi.org/10.1681/asn.2016060640.

El-Husseini A, Ahmed A, Sabucedo A, Fabulo E. Refractory Henoch-Schönlein purpura: atypical aetiology and management. J Ren Care 2013;39:77-81. https://doi.org/10.1111/j.17556686.2013.12007.x.

Fenoglio R, Naretto C, Basolo B, Quattrocchio G, Ferro M, Mesiano P, et al. Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature. Immunol Res 2017;65:186-192. https://doi.org/10.1007/s12026-016-8827-5.

Chancharoenthana W, Townamchai N, Leelahavanichkul A, Wattanatorn S, Kanjanabuch T, Avihingsanon Y, et al. Rituximab for recurrent IgA nephropathy in kidney transplantation: A report of three cases and proposed mechanisms. Nephrology (Carlton) 2017;22:65-71. https://doi.org/10.1111/nep.12722.

Chen X, Chen N. Plasma exchange in the treatment of rapidly progressive glomerulonephritis. Contrib Nephrol 2013;181:240-247. https://doi.org/10.1159/000348632.

Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int 2006;69:1939-1944. https://doi.org/10.1038/sj.ki.5000434.

Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int 2006;69:1934-1938. https://doi.org/10.1038/sj.ki.5000419.

Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 1999;78:395-409. https://doi.org/10.1097/00005792-199911000-00005.

Cheigh JS, Kim H, Stenzel KH, Tapia L, Sullivan JF, Stubenbord W, et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 1990;16:189-195. https://doi.org/10.1016/s0272-6386(12)81017-1.

Chagnac A, Kiberd BA, Fariñas MC, Strober S, Sibley RK, Hoppe R, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989;84:922-930. https://doi.org/10.1172/jci114254.

Raff A, Hebert T, Pullman J, Coco M. Crescentic post-streptococcal glomerulonephritis with nephrotic syndrome in the adult: is aggressive therapy warranted? Clin Nephrol 2005;63:375-380. https://doi.org/10.5414/cnp63375.

Roy S 3rd, Murphy WM, Arant BS Jr. Poststreptococcal crescenteric glomerulonephritis in children: comparison of quintuple therapy versus supportive care. J Pediatr 1981;98:403-410. https://doi.org/10.1016/s0022-3476(81)80703-2.

Cómo citar
1.
Nieto-Ríos JF, Giraldo-Serna MB, García- Prada CA, Lotero-Cadavid AF, Serna-Higuita LM, Arias LF. Glomerulonefritis rápidamente progresiva mediada por inmunocomplejos (tipo II). Revisión de la literatura. Med. Lab. [Internet]. 8 de julio de 2021 [citado 1 de agosto de 2021];25(3):569-80. Disponible en: https://medicinaylaboratorio.com/index.php/myl/article/view/449
Publicado
2021-07-08
Sección
Artículos de revisión
Crossref Cited-by logo